Veru Inc.: Addressing prostate cancer and spec pharma in urology. Zuclomiphene in Ph 2 treating hot flashes caused by hormone treatment for prostate cancer. VERU-111: oral, next-gen, antitubulin agent for treatment of castration and novel androgen blocking agent resistant metastatic prostate cancer, IND submitted late-2018. Advancing 4 new drug formulations in urology: Tadalafil/finasteride combo tablets for symptoms of BPH and erectile dysfunction (NDA filing exp 2H19). Tamsulosin DRS granules and XR capsules for benign prostatic hyperplasia (BPH) treatment w/o food effect (NDA filing exp 2019). Solifenacin DRG granules for overactive bladder in pts w difficulty swallowing. Pipeline supported by comml product revenue ($14M in 2017).
Healthcare/Drug Manufacturers
Based in...
Clinical Stage
Marketed, Phase l or ll
Disease Space
Men's Health, Oncology, Urology, Women's Health
Biotechnology, Specialty Pharmaceutical
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
4400 Biscayne Blvd Ste 888
Miami, FL 33137
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.